Alpha 2.0
Login Register
» Authors » Mohammad Jahanzeb

Mohammad Jahanzeb

Explore the profile of Mohammad Jahanzeb including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 71
Citations 2171
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Pharmacology
Top 10 Co-Authors
William J Gradishar
Antonio C Wolff
Eric P Winer
Hope S Rugo
Harold J Burstein
Lori J Goldstein
Robert W Carlson
David S Ettinger
Todd L Demmy
Debu Tripathy
Published In
J Natl Compr Canc Netw
Clin Breast Cancer
J Clin Oncol
Oncologist
Clin Lung Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
International experts consensus on optimal central vascular access device selection and management for patients with cancer
Jahanzeb M, Wu C, Lim H, Muro K, Xu L, Somashekhar M, et al.
J Vasc Access . 2024 Dec; :11297298241300792. PMID: 39620855
Background: In patients with cancer, the choice of an appropriate venous access device is crucial for effective treatment, minimizing complications, and reducing healthcare costs. Key management decisions, such as the...
2.
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Mezzanotte-Sharpe J, ONeill A, Mayer I, Arteaga C, Yang X, Wagner L, et al.
Breast Cancer Res Treat . 2024 Jul; 207(2):275-282. PMID: 38967884
Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the pre-clinical...
3.
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Mezzanotte-Sharpe J, ONeill A, Mayer I, Arteaga C, Yang X, Wagner L, et al.
Res Sq . 2024 May; PMID: 38746356
Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the preclinical...
4.
Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
Jahanzeb M, Lin H, Wu Y, Zhang P, Gorritz M, McGuiness C, et al.
Oncologist . 2022 Jul; 27(9):790-798. PMID: 35781589
Background: Real-world evidence for brigatinib, a next-generation anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) used in ALK-rearranged non-small cell lung cancer, is scarce. This retrospective study evaluated real-world brigatinib utilization in...
5.
Remarkable Role of Chemotherapy in Selected ALK-Positive Non-Small-Cell Lung Cancer Before or After Targeted Therapy: Two Case Reports
Gawri K, Dawar R, Haines K, Jahanzeb M
JCO Precis Oncol . 2022 Jan; 4:1425-1428. PMID: 35050790
No abstract available.
6.
Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial
Pierobon M, Robert N, Northfelt D, Jahanzeb M, Wong S, Hodge K, et al.
Mol Oncol . 2021 Aug; 16(1):104-115. PMID: 34437759
This prospective phase II clinical trial (Side Out 2) explored the clinical benefits of treatment selection informed by multi-omic molecular profiling (MoMP) in refractory metastatic breast cancers (MBCs). Core needle...
7.
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L)
Campelo M, Lin H, Zhu Y, Perol M, Jahanzeb M, Popat S, et al.
Lung Cancer . 2021 Mar; 155:68-77. PMID: 33744781
Objective: In ALTA-1 L, first-line brigatinib versus crizotinib significantly prolonged progression-free survival in advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC). We report health-related quality of life (HRQOL) outcomes from...
8.
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry
Kaufman P, Hurvitz S, OShaughnessy J, Mason G, Yardley D, Brufsky A, et al.
Breast Cancer Res Treat . 2021 Feb; 188(1):179-190. PMID: 33641083
Background: Systemic Therapies for HER2-Positive Metastatic Breast Cancer Study (SystHERs, NCT01615068) was a prospective, observational disease registry designed to identify treatment patterns and clinical outcomes in patients with HER2-positive metastatic...
9.
Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report
Mohammadi O, Haines K, Jahanzeb M
Cancer Treat Res Commun . 2021 Jan; 26:100291. PMID: 33388727
Tyrosine kinase inhibitors are the first-line treatment for Anaplastic Lymphoma Kinase-positive lung adenocarcinomas. However, chemotherapy is still an option in patients who are unresponsive or intolerant of tyrosine kinase inhibitors....
10.
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer
Jahanzeb M, Lin H, Pan X, Yin Y, Baumann P, Langer C
Clin Lung Cancer . 2020 Nov; 22(1):49-57. PMID: 33250347
Introduction: The treatment landscape for anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) primarily involves ALK-directed tyrosine kinase inhibitors (TKIs). Although therapy with immune checkpoint inhibitors (ICIs) is a treatment...